This observation supports the notion that true personalization in colorectal cancer (CRC) management necessitates the consideration of a triad comprising: (1) tumor genotype, (2) immune signature, which includes microsatellite instability (MSI), tumor mutational burden (TMB), and CD8+ T cell infiltration, (3) the microbial ecosystem. The gene discussed is CD8A; the disease is neoplasm.